171 related articles for article (PubMed ID: 35318116)
1. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
6. SIX1 reduces the expression of PTEN via activating PI3K/AKT signal to promote cell proliferation and tumorigenesis in osteosarcoma.
Yu C; Zhang B; Li YL; Yu XR
Biomed Pharmacother; 2018 Sep; 105():10-17. PubMed ID: 29807230
[TBL] [Abstract][Full Text] [Related]
7. Honokiol suppresses proliferation and induces apoptosis via regulation of the miR‑21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells.
Yang J; Zou Y; Jiang D
Int J Mol Med; 2018 Apr; 41(4):1845-1854. PubMed ID: 29393336
[TBL] [Abstract][Full Text] [Related]
8. miR-155 Affects Osteosarcoma MG-63 Cell Autophagy Induced by Adriamycin Through Regulating PTEN-PI3K/AKT/mTOR Signaling Pathway.
Wang L; Tang B; Han H; Mao D; Chen J; Zeng Y; Xiong M
Cancer Biother Radiopharm; 2018 Feb; 33(1):32-38. PubMed ID: 29412697
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.
Zhao G; Cai C; Yang T; Qiu X; Liao B; Li W; Ji Z; Zhao J; Zhao H; Guo M; Ma Q; Xiao C; Fan Q; Ma B
PLoS One; 2013; 8(1):e53906. PubMed ID: 23372675
[TBL] [Abstract][Full Text] [Related]
10. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway.
Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J
Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.
Liu B; Xu L; Dai EN; Tian JX; Li JM
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma.
Xu J; Chen C; Sun K; Shi Q; Wang B; Huang Y; Ren T; Tang X
Front Oncol; 2023; 13():1192472. PubMed ID: 37404767
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
Li KW; Wang SH; Wei X; Hou YZ; Li ZH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
[TBL] [Abstract][Full Text] [Related]
15. Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway.
Li D; Yang J; Ma H; Sun C; Feng R
J Cell Biochem; 2018 Dec; 119(12):9899-9909. PubMed ID: 30132953
[TBL] [Abstract][Full Text] [Related]
16. Diallyl trisulfide regulates cell apoptosis and invasion in human osteosarcoma U2OS cells through regulating PI3K/AKT/GSK3β signaling pathway.
He P; Wang Z; Sheng B; Xu Y; Feng S; Huang Y; Gong F; Tang L; Xie L
Histol Histopathol; 2020 Dec; 35(12):1511-1520. PubMed ID: 33372687
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
[TBL] [Abstract][Full Text] [Related]
18. Schisandrin B suppresses osteosarcoma lung metastasis
Wang Y; Chen J; Huang Y; Yang S; Tan T; Wang N; Zhang J; Ye C; Wei M; Luo J; Luo X
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029287
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of anlotinib-induced autophagy attenuates invasion and migration by regulating epithelial-mesenchymal transition and cytoskeletal rearrangement through ATG5 in human osteosarcoma cells.
Zheng B; Sun X; Zhang L; Qu G; Ren C; Yan P; Zhou C; Yue B
Braz J Med Biol Res; 2024; 57():e13152. PubMed ID: 38381883
[TBL] [Abstract][Full Text] [Related]
20. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
